Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...
Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...
Seven S&P 500 high-yield 'safer' dividend stocks—like Ford, AT&T, and VICI—offer strong payouts supported by free cash flow ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Tempus AI stock remains in a bear market after crashing by 36% from its highest point in September last year. What next for ...
MarketBeat on MSN
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The article " These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever " first appeared on MarketBeat.
What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share ...
A meaningful portion of AbbVie’s ABBV revenues comes from its oncology franchise. Initially anchored by blood cancer drugs ...
Zacks Investment Research on MSN
LLY up 28% in 3 months: Is it the right time to invest in the stock?
Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, ...
Global defence share prices and revenues have soared thanks to higher military spending since the start of Russia’s ...
Amgen is not alone in pursuing such agreements. Eight other large-cap drugmakers — Bristol Myers BMY, GSK plc GSK, Merck MRK, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback